Trial Profile
A study comparing efficacy and safety of oral rivaroxaban and subcutaneous low molecular weight heparin maintenance therapy for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Low molecular weight heparins
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress